Transaction · 0000905148-26-003836

Masson Kristina

Masson Kristina, EVP - Business Operations, reported an open-market or private sale at Acrivon Therapeutics, Inc. involving 1229.000000 shares for an estimated $2470.29. Reported holdings after the transaction were 2244088.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SEBO
ACRVAcrivon Therapeutics, Inc.
Filing timeAug 20
Trade dateAug 18, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$2.20
Pre-filing
1mo ago -20.5%1w ago -21.4%1d ago -7.3%
Returns since
7d -2.3%30d -6.4%90d -6.4%180d -6.4%1y -6.4%

ACRV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ACRV since 2026-08-20Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000905148-26-003836
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 08:07 PM · 2d delay
Shares
1.22k sh
$201 per share
Estimated value
-$247k
Computed from shares × price
Holdings after
2.24M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP - Business Operations

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

  2. F2

    These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of h…

  3. F3

    These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of…

Original filing · 0000905148-26-003836
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ACRV